Business
Castle Biosciences Collaborates with the National Cancer Institute to Link DecisionDx®-Melanoma Testing Data with SEER Registries’ Cutaneous Melanoma Cases
Analysis of the first subset of linked SEER patient data demonstrates DecisionDx®-Melanoma testing was associated with improved overall survival rates
About this update from Castle Biosciences, Inc.
[{"type":"text","content":"\nAnalysis of the first subset of linked SEER patient data demonstrates DecisionDx®-Melanoma testing was associated with improved overall survival rates compared to untested patients\n\nDecisionDx-Melanoma stratifies patient risk of death in an unselected, prospectively tested population of patients 65 years and older, consistent with prior study cohorts\n\n FRIENDSWOOD, Texas--(BUSINESS WIRE)--\nCastle Biosciences, Inc. (Nasdaq: CSTL), a leader in transforming disease management and improving patient outcomes through innovative diagnostics, today announced a collaboration with the National Cancer Institute (NCI) to link DecisionDx®-Melanoma testing data with data from the Surveillance, Epidemiology and End Results (SEER) Program’s registries on cutaneous melanoma (CM) cases.\n\nCM cases in the SEER registries that were diagnosed between 2013-2018 were linked with DecisionDx-Melanoma results and additional clinicopathologic information from patients tested between 2013-2018. The Company expects to continue collaborating with the NCI to link the SEER registries’ CM cases diagnosed post-2018 with DecisionDx-Melanoma test results. The initial linked dataset is expected to be broadly available to interested researchers through the standard data request process for SEER Specialized Datasets in 2022.\n\nData analysis from the first subset of patients was shared in a poster presentation at the 2022 Winter Clinical Dermatology Conference, held Jan. 14-19 in Koloa, Hawaii.\n\n“We are excited to collaborate with the NCI to link DecisionDx-Melanoma test results with the SEER registries’ data,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “Castle is committed to providing clinically actionable tests to improve patient outcomes. Analysis from the first subset of patients (65 years or older at time of diagnosis and diagnosed in 2016 or later) provides real-world evidence of the capability of our test to do just that. Specifically, when controlling for demographic and clinicopathological variables, patients tested with DecisionDx-Melanoma had better overall survival rates over 2.5 years than patients not tested.”\n\nThe poster, titled “31-gene expression profile testing survival benefit in a population-based analysis of cutaneous melanoma patients ≥65 years of age,” highlighted the first analysis of Castle’...